Winship, within the broader community of Emory University, participates with four full research programs and a number of developing research programs. Each program is comprised of a critical mass of Emory investigators whose cancer research interests in a particular area are complementary and synergistic. Numerous opportunities for collaborative studies and large team science research endeavors result from a variety of intra and interprogrammatic activities.
Cancer Cell Biology (CCB)
The Cancer Cell Biology (CCB) Program encompasses a tightly knit team of scientists grouped around the central thematic of tumor signaling in the context of inter- and intra-cellular signaling modulated by tumor microenvironment, and its ramifications for the development of prevention, prediction, biomarker and therapeutic target discovery and drug development. Read more.
Cancer Prevention and Control (CPC)
The Cancer Prevention and Control (CPC) Program organizes all of the cancer prevention-related research activities of the Winship Cancer Institute. These activities span the cancer prevention continuum from primary to secondary to tertiary prevention at the individual, select population, and societal levels. Read more.
Cancer Genetics and Epigenetics (CGE)
The overall goal of the Cancer Genetics and Epigenetics (CGE) Program is to decrease human cancer mortality through obtaining a better understanding of fundamental genetic alterations occurring at the DNA and chromatin levels that are responsible for the initiation, development and progression of tumors and influence responses to therapy. DNA damage, genetic mutations, genomic instability and DNA and chromatin-targeted molecular transactions that alter gene expression programs are all critical events that contribute to the development of cancers in humans. Read more.
Discovery and Developmental Therapeutics (DDT)
The primary mission of the Winship Cancer Institute Discovery and Developmental Therapeutics (DDT) Program is to foster a collaborative team research environment to promote molecular target interrogation for cancer drug discovery and to facilitate translational clinical trials for effective therapeutic development. Read more.